Tyr641 is a functional acquired EZH2 mutation that promotes the growth of B-cell lymphoma and melanoma, characterized by high expression levels of the anti-apoptotic protein Bcl2 and loss of the tumor inhibitor p53 [11]. Here, EZH2 is linked to B-cell non-Hodgkin lymphoma.